Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia

European Journal of Haematology

Volumn 57, Issue 1, 1996, Pages 87-95

  Bruserud, Øystein ^a,b   Aasen, Ingrid ^a   Akselsen, Per Espen ^a   Bergheim, Jann ^a   Rasmussen, Gro ^a   Nesthus, Ingrid ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute leukaemia; Bacterial infections; Interleukin 1 receptor antagonist; Interleukin 1 ; Leucopenia

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUCONAZOLE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METRONIDAZOLE; MITOXANTRONE; NETILMICIN; PENICILLIN G; TIOGUANINE; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; GRANULOCYTOPENIA; HUMAN; MALE; MYCOSIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; TREATMENT OUTCOME;

EID: 0029998207     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00495.x     Document Type: Article

References (30)

1. DINARELLO CA. Interleukin 1 and Interleukin 1 antagonism. Blood 1991: 77: 1627-1652.
2. SAKAI K, HATTORI T, MATSCOKA M, et al. Autocrine stimulation of Interleukin 1βin acute myelogenous leukemia cells. J Exp Med 1987: 166: 1597-1602.
3. COZZOLINO F, RUBARTELLI A, ALDINUCCI D, et al. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci 1989: 86: 2369-2373.
4. RAMBALDI A, TORCIA M, BETTONI S, et al. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by Interleukin 1 receptor antagonist and lack of its expression by leukemic cells. Blood 1991: 78: 3248-3253.
5. BRUSERUD Ø. Effects of endogenous Interleukin 1 on blast cells derived from acute myelogenous leukemia patients. Leukemia Res 1996: 20: 63-71.
6. OSTERMANN H, ROTHENBURGER M, MESTERS RM, VAN DE LOO J, KIENAST J. Cytokine response to infection in patients with acute myelogenous leukemia following intensive chemotherapy. Br J Haematol 1994: 88: 332-337.
7. BRUSERUD Ø, BERGHEIM J, SHAMMAS FV, NESTHUS I. Serum concentrations of tumor necrosis factor-α during chemotherapy-induced leukopenia in patients with acute leukaemia and bacterial infections. Leukemia Res 1994: 18: 415-421.
8. RINTALA E, PULKKI K, MERTSOLA J, NEVALAINEN T, NIKOSKELAINEN J. Endotoxin, Interleukin 6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 1995: 27: 39-43.
9. STEINSHAMN S, BREKKE O-L, WAAGE A. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin 6 in serum in granulocytopenic patients with fever. Br J Haematol 1995: 89: 719-724.
10. BRUSERUD Ø, AKSELSEN PE, BERGHEIM J, NESTHUS I. Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leukopenia and bacterial infections. Br J Haematol 1995: 91: 394-402.
11. GRANOWITZ EV, PORAT R, MIER JW, et al. Hematologic and immunomodulatory effects of an Interleukin 1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 1993: 82: 2985-2990.
12. CHRISTMAN JW. Potential treatment of sepsis syndrome with cytokine-specific agents. Chest 1992: 102: 613-617.
13. FISHER CJ, DHAINAUT JF, OPAL SM, et al. Recombinant human Interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994: 271: 1836-1843.
14. PAWELEC G. Immune surveillance in leukemia: rationale for immunotherapy. Hematol Rev 1994: 8: 123-147.
15. BRACH M, STONE R, KUFE D. CSFs in combination with cytosine arabinoside, an inhibitor of DNA synthesis; potential strategies for the treatment of myeloid disorders. Biotech Ther 1991: 2: 269-283.
16. HOLLINGSHEAD LM, GOA KL. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991: 42: 300-330.
17. COSTELLO RT. Therapeutic use of Granulocyte-macrophage colony-stimulating factor (GM-CSF). Acta Oncol 1993: 32: 403-408.
18. BENNET JM, CATOWSKY D, DANIEL MT, et al. Proposals for the classification of the acute leukemias. Br J Haematol 1976; 33: 451-458.
19. KERANGEUVEN F, SEMPERE C, TABILIO A, MANNONI P. Effects of transforming growth factor beta, tumor necrosis factor alpha, interferon gamma and LIF-HILDA on the proliferation of acute myeloid leukemia cells. Eur Cytokine Netw 1990: 1: 99-107.
20. ASANO Y, OKAMURA S, SHIBUYA T, HARADA M, NIHO Y. Growth of clonogenic myeloblastic leukemia cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors. Blood 1988: 72: 1682-1686.
21. VELLENGA E, DEWOLF JTM, BEENTJES JAM, ESSELINK MT, SMIT JW, HALIE MR. Divergent effects of Interleukin 4 on the granulocyte colony-stimulating factor and IL3-supported myeloid colony formation from normal and leukemic bone marrow cells. Blood 1990: 75: 633-637.
22. LEMOLI RM, GULATI SC, STRIFE A, LAMBEK C, PEREZ A, CLARKSON BD. Proliferative response of acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL3, GM-CSF and G-CSF. Leukemia 1991: 5: 386-391.
23. CAROW CE, HANGOC G, COOPER SH, WILLIAMS DE, BROXMEYER HE. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential. Blood 1991: 78: 2216-2221.
24. BRUSERUD Ø, GJERTSEN BT, BRUSTUGUN OT, et al. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia, 1995: 9: 1910-1920.
25. BRUSERUD Ø, NESTHUS I, BÜHRING H-J, PAWELEC G. Cytokine modulation of interleukin 1 and tumor necrosis factor α secretion from acute myelogenous leukemia blast cells in vitro. Leukemia Res 1995: 19: 15-22.
26. SISSOLAK G, HOFFBRAND AV, METHA AB, GANESHAGURU K. Effects of interferon a on the expression of interferon β, interleukin 6, granulocyte/macrophage-colony stimulating factor and tumor necrosis factor a in acute myeloid leukemia blasts. Leukemia 1992: 6: 1155-1160.
27. McGLAVE PB, HAAKE RJ, BOSTROM BC, et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 1988: 72: 1512-1517.
28. SCAPIGLIATI G, GHIARA P, BARTALINI A, TAGLIBUE A, BORASCHI D. Differential binding of IL1α and IL1β to receptors on B and T cells. FEBS Lett 1989: 243: 394-398.
29. ROGY MA, COYLE SM, OLDENBURG HSA, et al. Persistently elevated soluble tumor necrosis factor receptor and Interleukin 1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994: 178: 132-138.
30. MOLDAWER LL. Interleukin 1, TNFα and their naturally occurring antagonists in sepsis. Blood Purif 1993: 11: 128-133.